Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: Drugs Old & New, Equitable Access To Vaccines, And Vial Supplies

Executive Summary

In this edition of the Coronavirus Notebook, an EU consortium uses a supercomputing platform to identify the generic drug raloxifene as a potential COVID-19 treatment, and the World Health Organization proposes a set of principles for distributing a coronavirus vaccine at global level.

You may also be interested in...



Coronavirus Notebook: Dexamethasone Reduces Deaths In Hospitalized COVID-19 Patients

The standout development in this latest Coronavirus Notebook is that the cheap and plentiful steroid dexamethasone has been shown to reduce deaths by a third in ventilated COVID-19 patients in the UK Recovery trial. In other news, there is fresh funding for smaller firms working on potential treatments and vaccines, and a number of organizations have decided to make their research tools and resources available free of charge in return for open publication of any coronavirus-related findings.

Swiss Finally Beat EMA On New Drug Approval Times

More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.

UK Beefs Up Health Security Body With New Vaccine Supply Role

The UK government says that the UKHSA will be able to “harness the strengths” of the Vaccines Taskforce, including its “excellent relationships with industry” and “expertise in innovation.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel